Iruya Therapeutics Reports Q3 GAAP EPS of -$2.31, Exceeding Analyst Expectations
Iruya Therapeutics (IRLA) reported third-quarter GAAP earnings per share of -$2.31, which outperformed market expectations by $0.82. While the company remains in a loss position, the result represents a significant beat relative to consensus estimates. As of September 30, 2026, the company held $105.2 million in cash, cash equivalents, and investments. Management stated that this current liquidity position is expected to be sufficient to fund ongoing operations through the end of 2028.
